Status: Recruiting
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
Participants needed: 200
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Sichuan Provincial People's HospitalUpdated: Jan 15, 2026Locations: 1
Eligibility criteria
Target patients aged 18-75, including those aged 18 and 75 [+4]
Including but not limited to secondary IgAN caused by allergic purpura, systemic... [+17]